JUPITER NEUROSCIENCES INC (JUNS) Stock Fundamental Analysis

NASDAQ:JUNS • US48208B2034

0.555 USD
-0.01 (-0.89%)
Last: Feb 18, 2026, 03:28 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Overall JUNS gets a fundamental rating of 1 out of 10. We evaluated JUNS against 191 industry peers in the Pharmaceuticals industry. JUNS has a bad profitability rating. Also its financial health evaluation is rather negative. JUNS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • JUNS had negative earnings in the past year.
  • JUNS had a negative operating cash flow in the past year.
  • In the past 5 years JUNS always reported negative net income.
  • In the past 5 years JUNS always reported negative operating cash flow.
JUNS Yearly Net Income VS EBIT VS OCF VS FCFJUNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

  • The Return On Assets of JUNS (-148.62%) is worse than 85.34% of its industry peers.
  • JUNS's Return On Equity of -440.08% is on the low side compared to the rest of the industry. JUNS is outperformed by 79.06% of its industry peers.
Industry RankSector Rank
ROA -148.62%
ROE -440.08%
ROIC N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
JUNS Yearly ROA, ROE, ROICJUNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

1.3 Margins

  • JUNS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JUNS Yearly Profit, Operating, Gross MarginsJUNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • The number of shares outstanding for JUNS has been increased compared to 1 year ago.
  • Compared to 5 years ago, JUNS has more shares outstanding
  • Compared to 1 year ago, JUNS has an improved debt to assets ratio.
JUNS Yearly Shares OutstandingJUNS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
JUNS Yearly Total Debt VS Total AssetsJUNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M

2.2 Solvency

  • JUNS has an Altman-Z score of -10.84. This is a bad value and indicates that JUNS is not financially healthy and even has some risk of bankruptcy.
  • JUNS's Altman-Z score of -10.84 is on the low side compared to the rest of the industry. JUNS is outperformed by 71.73% of its industry peers.
  • JUNS has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.11, JUNS perfoms like the industry average, outperforming 49.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -10.84
ROIC/WACCN/A
WACCN/A
JUNS Yearly LT Debt VS Equity VS FCFJUNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M -6M

2.3 Liquidity

  • JUNS has a Current Ratio of 1.07. This is a normal value and indicates that JUNS is financially healthy and should not expect problems in meeting its short term obligations.
  • JUNS has a Current ratio of 1.07. This is amonst the worse of the industry: JUNS underperforms 83.25% of its industry peers.
  • JUNS has a Quick Ratio of 1.07. This is a normal value and indicates that JUNS is financially healthy and should not expect problems in meeting its short term obligations.
  • JUNS has a worse Quick ratio (1.07) than 78.01% of its industry peers.
Industry RankSector Rank
Current Ratio 1.07
Quick Ratio 1.07
JUNS Yearly Current Assets VS Current LiabilitesJUNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • JUNS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.67%, which is quite impressive.
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • JUNS is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -73.25% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JUNS Yearly Revenue VS EstimatesJUNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2M 4M 6M 8M 10M
JUNS Yearly EPS VS EstimatesJUNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 0 -0.1 -0.2

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • JUNS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • JUNS is valuated reasonably with a Price/Forward Earnings ratio of 9.07.
  • 89.53% of the companies in the same industry are more expensive than JUNS, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 28.10. JUNS is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 9.07
JUNS Price Earnings VS Forward Price EarningsJUNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JUNS Per share dataJUNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15

4.3 Compensation for Growth

  • JUNS's earnings are expected to decrease with -73.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y78.89%
EPS Next 3Y-73.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • JUNS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JUPITER NEUROSCIENCES INC

NASDAQ:JUNS (2/18/2026, 3:28:42 PM)

0.555

-0.01 (-0.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14
Earnings (Next)N/A
Inst Owners3.95%
Inst Owner Change-55.97%
Ins Owners45.96%
Ins Owner Change0%
Market Cap19.11M
Revenue(TTM)N/A
Net Income(TTM)-5.90M
Analysts82.86
Price Target25.5 (4494.59%)
Short Float %3.53%
Short Ratio1.7
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.72%
Min EPS beat(2)-63.4%
Max EPS beat(2)1.96%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-57.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.07
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.26
P/tB 14.26
EV/EBITDA N/A
EPS(TTM)-0.18
EYN/A
EPS(NY)0.06
Fwd EY11.03%
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -148.62%
ROE -440.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-1786.7%
ROA(5y)-1258.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.07
Quick Ratio 1.07
Altman-Z -10.84
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-800%
EPS Next Y-420%
EPS Next 2Y78.89%
EPS Next 3Y-73.25%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-714.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-714.93%
OCF growth 3YN/A
OCF growth 5YN/A

JUPITER NEUROSCIENCES INC / JUNS FAQ

What is the ChartMill fundamental rating of JUPITER NEUROSCIENCES INC (JUNS) stock?

ChartMill assigns a fundamental rating of 1 / 10 to JUNS.


Can you provide the valuation status for JUPITER NEUROSCIENCES INC?

ChartMill assigns a valuation rating of 2 / 10 to JUPITER NEUROSCIENCES INC (JUNS). This can be considered as Overvalued.


How profitable is JUPITER NEUROSCIENCES INC (JUNS) stock?

JUPITER NEUROSCIENCES INC (JUNS) has a profitability rating of 0 / 10.


What is the earnings growth outlook for JUPITER NEUROSCIENCES INC?

The Earnings per Share (EPS) of JUPITER NEUROSCIENCES INC (JUNS) is expected to decline by -420% in the next year.